ECSP045146A - Moléculas pequeñas para el tratamiento del crecimiento celular anormal - Google Patents

Moléculas pequeñas para el tratamiento del crecimiento celular anormal

Info

Publication number
ECSP045146A
ECSP045146A EC2004005146A ECSP045146A ECSP045146A EC SP045146 A ECSP045146 A EC SP045146A EC 2004005146 A EC2004005146 A EC 2004005146A EC SP045146 A ECSP045146 A EC SP045146A EC SP045146 A ECSP045146 A EC SP045146A
Authority
EC
Ecuador
Prior art keywords
small molecules
treatment
cell growth
abnormal cell
erbb2
Prior art date
Application number
EC2004005146A
Other languages
English (en)
Inventor
John Charles Kath
James Dale Moyer
Richard Damian Connell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP045146A publication Critical patent/ECSP045146A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a moléculas pequeñas que son útiles en el tratamiento del crecimiento celular anormal, tal como el cáncer, en mamíferos. Esta invención también se refiere a un procedimiento de uso de tales moléculas pequeñas en el tratamiento del crecimiento celular anormal en mamíferos, especialmente en seres humanos, y a composiciones farmacéuticas que contienen tales compuestos. La invención se refiere además a pequeñas moléculas que son selectivas para el receptor erbB2 respecto al receptor erbB1, teniendo dicho inhibidor de erbB2 un intervalo de selectividades por erbB2 respecto a erbB1 entre 50-1500
EC2004005146A 2001-12-12 2004-06-10 Moléculas pequeñas para el tratamiento del crecimiento celular anormal ECSP045146A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34109101P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
ECSP045146A true ECSP045146A (es) 2004-07-23

Family

ID=23336198

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005146A ECSP045146A (es) 2001-12-12 2004-06-10 Moléculas pequeñas para el tratamiento del crecimiento celular anormal

Country Status (29)

Country Link
US (1) US20030171386A1 (es)
EP (1) EP1465632A1 (es)
JP (1) JP4181502B2 (es)
KR (1) KR20040063948A (es)
CN (1) CN1602195A (es)
AP (1) AP2004003058A0 (es)
AR (1) AR037771A1 (es)
AU (1) AU2002339687A1 (es)
BR (1) BR0214499A (es)
CA (1) CA2469670A1 (es)
DO (1) DOP2002000545A (es)
EA (1) EA200400680A1 (es)
EC (1) ECSP045146A (es)
GT (1) GT200200273A (es)
HR (1) HRP20040529A2 (es)
HU (1) HUP0501069A2 (es)
IL (1) IL161908A0 (es)
IS (1) IS7233A (es)
MA (1) MA27154A1 (es)
MX (1) MXPA04004107A (es)
NO (1) NO20042882L (es)
OA (1) OA12734A (es)
PA (1) PA8561301A1 (es)
PE (1) PE20030760A1 (es)
PL (1) PL373848A1 (es)
TN (1) TNSN04111A1 (es)
TW (1) TW200301121A (es)
WO (1) WO2003049740A1 (es)
ZA (1) ZA200404264B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
AU2003303045A1 (en) * 2002-12-18 2004-07-09 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
MXPA05006582A (es) * 2002-12-19 2005-08-16 Pfizer Prod Inc Complejos de e-2-metoxi -n-(3 -{4-[3 -metil-4 -(6-metilpiridin -3- iloxi) fenilamino] quinazolin -6-il} alil) acetamida, su procedimiento de produccion y uso.
MXPA06001989A (es) * 2003-08-18 2006-05-17 Pfizer Prod Inc Programa de dosificacion para un nuevo agente anticanceroso.
SI2213661T1 (sl) * 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
US20050245508A1 (en) * 2003-12-24 2005-11-03 Scios, Inc. Treatment of malignant gliomas with TGF-beta inhibitors
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
CA2610491A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Bicyclic derivatives for the treatment of abnormal cell growth
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
BRPI0720169A2 (pt) 2006-12-12 2013-12-24 Takeda Pharmaceutical Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US20090233937A1 (en) 2008-03-12 2009-09-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CA2723989C (en) 2008-05-13 2017-04-25 Astrazeneca Ab Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
WO2010015522A1 (de) 2008-08-08 2010-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
CN104024432B (zh) 2011-08-31 2017-02-22 基因泰克公司 诊断性标志物
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
US10287401B2 (en) 2015-07-01 2019-05-14 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3806887A4 (en) 2018-06-13 2022-04-06 California Institute of Technology NANOPARTICLES FOR CROSSING THE BLOOD-BRAIN BARRIER AND METHODS OF TREATMENT USING IT
JP2023512175A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
JP2023512174A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
CN113429390B (zh) * 2020-03-23 2022-04-15 苏州恩华生物医药科技有限公司 喹唑啉衍生物及其应用
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
DE60037020T2 (de) * 1999-07-09 2008-08-21 Glaxo Group Ltd., Greenford Anilinochinazoline als protein-tyrosin-kinasehemmer
EE05107B1 (et) * 1999-10-19 2008-12-15 Merck & Co., Inc. Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine
PL359557A1 (en) * 2000-06-22 2004-08-23 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
EP1456199A1 (en) * 2001-12-12 2004-09-15 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Also Published As

Publication number Publication date
GT200200273A (es) 2003-10-03
PL373848A1 (en) 2005-09-19
IL161908A0 (en) 2005-11-20
TW200301121A (en) 2003-07-01
PE20030760A1 (es) 2003-09-05
JP2005527486A (ja) 2005-09-15
HRP20040529A2 (en) 2004-10-31
CA2469670A1 (en) 2003-06-19
OA12734A (en) 2006-06-28
PA8561301A1 (es) 2003-12-30
AR037771A1 (es) 2004-12-01
EA200400680A1 (ru) 2005-06-30
WO2003049740A1 (en) 2003-06-19
AU2002339687A1 (en) 2003-06-23
TNSN04111A1 (fr) 2006-06-01
AP2004003058A0 (en) 2004-06-30
BR0214499A (pt) 2005-05-10
MXPA04004107A (es) 2004-07-23
IS7233A (is) 2004-04-26
CN1602195A (zh) 2005-03-30
JP4181502B2 (ja) 2008-11-19
KR20040063948A (ko) 2004-07-14
US20030171386A1 (en) 2003-09-11
HUP0501069A2 (en) 2006-06-28
DOP2002000545A (es) 2003-06-16
NO20042882L (no) 2004-07-07
EP1465632A1 (en) 2004-10-13
ZA200404264B (en) 2005-08-31
MA27154A1 (fr) 2005-01-03

Similar Documents

Publication Publication Date Title
ECSP045146A (es) Moléculas pequeñas para el tratamiento del crecimiento celular anormal
ECSP066406A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
PA8680701A1 (es) Derivados de oxindol
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
HN2003000422A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
PA8643201A1 (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
UY25794A1 (es) Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
NI200900190A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal. pc33495a
UY28894A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
UY29685A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.
AR018201A1 (es) Compuesto de mesilato de n-(3-etinilfenil)-6,7-bis-(2-metoxietoxi)-4-quinazolinamina, composiciones que los contienen y su uso de dichos compuestos para la preparacion de medicamentos.
UY29645A1 (es) Derivados de pirido(2,3-d)pirimidina, su preparacion, su aplicacion en terapeutica
ECSP045219A (es) Derivados de quinazolinona y su uso como agonistas cb
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
AR056279A1 (es) Derivados de aril 1,4- pirazina sustituidos, composicion farmaceutica y un metodo in vitro
CR7989A (es) 7-alquinilamino- triazolopirimidinas, procedimientos para su obtencion y el uso de las mismas para controlar hongos nocivos, asi como productos que la contienen
PE20061042A1 (es) Derivados de 5-fenilpirimidina como agentes para el tratamiento del cancer
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
AR026209A1 (es) Compuestos monociclicos basicos con accion nk-2 antagonista, procesos de fabricacion y formulas que los contienen